Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
After Judge Denise Cotes banned Martin Shkreli from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
Moderna, Pfizer and BioNTech and Johnson & Johnson earned an approximate combined revenue of $31 billion in 2021, thanks to the success of their mRNA vaccines against COVID-19.
In Moderna’s fourth-quarter 2021 annual report, the company announced $7.2 billion in fourth-quarter revenues and full-year 2021 revenues of $18.5 billion.
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
Jeffrey D. Marrazzo, the co-founder of Spark Therapeutics, is stepping down as CEO of the company. The current COO, Ron Philip, will replace him.
The arrangement provides the opportunity for LJI faculty and postdocs to make a more immediate impact on drug development while offering a different perspective to KKNA.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.